机构

• 上海药物研究所 [7]
• 合肥物质科学研究院 [5]
• 上海生物化学与细胞生... [3]
• 金属研究所 [2]
• 大连化学物理研究所 [2]
• 化学研究所 [1]
• 更多

采集方式

• OAI收割 [20]
• iSwitch采集 [2]

内容类型

• 期刊论文 [22]

发表日期

• 2024 [1]
• 2023 [1]
• 2022 [3]
• 2021 [1]
• 2020 [3]
• 2019 [2]
• 更多

学科主题

• Oncology; ... [2]
• Oncology [1]
• Respirator... [1]

筛选

浏览/检索结果: 共22条，第1-10条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择题名升序题名降序提交时间升序提交时间降序作者升序作者降序发表日期升序发表日期降序 D3EGFR: a webserver for deep learning-guided drug sensitivity prediction and drug response information retrieval for EGFR mutation-driven lung cancer 期刊论文  OAI收割 BRIEFINGS IN BIOINFORMATICS, 2024, 卷号: 25, 期号: 3, 页码: 10 作者:  Shi, Yulong;  Li, Chongwu;  Zhang, Xinben;  Peng, Cheng;  Sun, Peng   |  收藏  |  浏览/下载：42/0  |  提交时间：2024/05/07 lung cancer  EGFR mutation  drug sensitivity prediction  patient case database  deep learning   Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo 期刊论文  OAI收割 JOURNAL OF CANCER, 2023, 卷号: 14, 期号: 1, 页码: 152-162 作者:  Lai, Mengzhen;  Zhang, Tao;  Chen, Hao;  Song, Peiran;  Tong, Linjiang   |  收藏  |  浏览/下载：122/0  |  提交时间：2023/04/10 fourth-generation EGFR inhibitor  EGFRC797S mutation  NSCLC  drug resistance  small molecular inhibitor   Gefitinib enhances the anti-tumor immune response against EGFR-mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H 期刊论文  OAI收割 INTERNATIONAL JOURNAL OF ONCOLOGY, 2022, 卷号: 61 作者:  Guo, Huihui;  Zhang, Xilin;  Xie, Shangzhi;  Chen, Tianwei;  Xie, Dong   |  收藏  |  浏览/下载：110/0  |  提交时间：2022/12/22 gefitinib  CD28H  NSCLC  EGFR mutation   Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib 期刊论文  OAI收割 BMC CANCER, 2022, 卷号: 22 作者:  Jin, Ying;  Lin, Chen;  Shi, Xun;  He, Qiong;  Yan, Junrong   |  收藏  |  浏览/下载：86/0  |  提交时间：2022/12/23 Clinical and molecular features  Efficacy and outcome  EGFR T790M mutation  Non-small-cell lung cancer  Osimertinib   Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR(T790M/C797S) Mutants 期刊论文  OAI收割 ACS MEDICINAL CHEMISTRY LETTERS, 2022, 页码: 7 作者:  Li, Shan;  Zhang, Tao;  Zhu, Su-Jie;  Lei, Chong;  Lai, Mengzhen   |  收藏  |  浏览/下载：41/0  |  提交时间：2022/06/15 Epidermal Growth Factor Receptor (EGFR)  Resistant Mutation  C797S  Antitumor   Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs) 期刊论文  OAI收割 ANNALS OF PALLIATIVE MEDICINE, 2021 作者:  Si, Jinfei;  Gu, Xiaodong;  Wang, Wenxian;  Ying, Shenpeng;  Song, Zhengbo   |  收藏  |  浏览/下载：86/0  |  提交时间：2022/02/14 Epidermal growth factor receptor (EGFR)  uncommon mutation  compound mutation  double uncommon mutation  lung adenocarcinoma (lung AC)   Safety, Clinical Activity, and Pharmacokinetics of Al flutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation 期刊论文  OAI收割 JOURNAL OF THORACIC ONCOLOGY, 2020, 卷号: 15, 期号: 6, 页码: 1015-1026 作者:  Shi, Yuankai;  Zhang, Shucai;  Hu, Xingsheng;  Feng, Jifeng;  Ma, Zhiyong   |  收藏  |  浏览/下载：103/0  |  提交时间：2020/12/24 Alflutinib  NSCLC  EGFR T790M mutation  Efficacy  Safety   Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non-Small Cell Lung Cancer 期刊论文  OAI收割 FRONTIERS IN ONCOLOGY, 2020, 卷号: 10 作者:  Lin, Chen;  Shi, Xun;  Zhao, Jun;  He, Qiong;  Fan, Yun   |  收藏  |  浏览/下载：78/0  |  提交时间：2020/10/26 tumor mutation burden (TMB)  clinical benefit  epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)  chemotherapy  non-small cell lung cancer (NSCLC)   BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFR(T790M) mutation 期刊论文  OAI收割 THERANOSTICS, 2020, 卷号: 10, 期号: 14, 页码: 6122-6135 作者:  Yin, Weimin;  Zhao, Yuge;  Kang, Xuejia;  Zhao, Pengfei;  Zhao, Xuhong   |  收藏  |  浏览/下载：96/0  |  提交时间：2020/07/01 brain targeting delivery  tumor-associated macrophage  non-small cell lung cancer (NSCLC)  drug resistance  tyrosine kinase inhibitors (TKI)  EGFR T790M mutation   EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC 期刊论文  OAI收割 JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 卷号: 38, 页码: 15 作者:  Qin, Jianhua;  Liu, Yang;  Yin, Yalei;  Sun, Mingju;  Zhan, Xi   |  收藏  |  浏览/下载：117/0  |  提交时间：2019/06/20 Bromodomain  JQ1  MAPK pathway  MYC  EGFR mutation  Sorafenib